COVID-19: consider cytokine storm syndromes and immunosuppression
By Puja Mehta, Daniel F McAuley, Michael Brown, Emilie Sanchez, R. Tattersall, Jessica J. Manson. The Lancet, 2020
8,587 citations recorded by the source corpus.
www.thelancet.com Published online March 13, 2020 https://doi.org/10.1016/S0140-6736(20)30628-0 1 Submissions should be made via our electronic submission system at http://ees.elsevier.com/ thelancet/ However, in hyperinflammation, immunosuppression is likely to be beneficial. Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events. A multicentre, randomised con trolled trial of tocilizumab (IL-6 receptor blockade, licensed for cytokine release syndrome), has been approved in patients with COVID-19: consider cytokine storm syndromes and immunosuppression
Subfields: Hematology, Immunology, Surgery
View Paper: https://www.semanticscholar.org/paper/b22d904367e842a6616cafe8a0d2905a3ee2a28e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Immunology
In Surgery
Citations in the corpus
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (2020, neutral): “The trial site in South Korea received funding from the Seoul National University Hospital.”
- Nervous system involvement after infection with COVID-19 and other coronaviruses (2020, positive): “The infection of CoV, especially SARS-CoV-2, has been widely reported to cause cytokine storm syndromes, which may be one of the factors that CoV cause acute cerebrobasilar disease (Mehta et al., 2020; Chen et al., 2020).”
- Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes (2020, positive): “A direct correlation between systemic increases in pro-inflammatory cytokines and lung injury, multiple organ failure, and unfavorable prognosis in patients with severe COVID-19 has been suggested, and uncontrolled cytokine signaling can contribute to multi-organ damage (Jose and Manuel, 2020; Mehta”
- Proteomic and Metabolomic Characterization of COVID-19 Patient Sera (2020, neutral): “, 2020), resulting in release of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a) (Mehta et al., 2020) by macrophages (Gabay and Kushner, 1999).”
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy (2020, neutral): “The scarcely available evidence suggests that a hyperinflammatory syndrome (HIS) that resembles secondary hemophagocytic lymphohistiocytosis (sHLH) may have a pathogenetic role [4,5].”
- Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment (2020, neutral): “The whole pathologic process starting with defects in lymphocyte cytolytic activity, going on with increased macrophage activity and whole immune system activation, resulting in a cytokine storm, ARDS, and multiorgan failure, is also called as MAS [3, 22, 23].”
- Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) (2020, neutral): “Some authors even suggest that we screen critically ill COVID-19 patients for secondary HLH using the Hscore (140), and that corticosteroids and other immunosuppressive agents can be used in patients with a high likelihood of HLH (141).”
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, neutral): “Nevertheless, it is yet unknown whether these hemos tatic changes are a specific effect of SARS-CoV-2 or are a consequence of cytokine storm t hat precipitates the onset of systemic inflammatory response syndrome (SIRS), as observed in other viral disease (30-33).”